Biosafety testing of GMP mcbs and retroviral vectors for NCI clinical trials
Ended Awarded Last action
- Contract number
- HHSN26100001
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $0
Award facts
- Opportunity
-
- N02RC3600485 Solicitation number
- Biosafety Testing of GMP Master Cell Banks (MCB) and Retroviral Vectors for NCI Clinical Trials Award Notice · Posted Mar 7, 2013
- Contract value
- $0.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$134,772 | |
| Original award | $134,772 |
Quick answers
Who was awarded contract HHSN26100001?
HHSN26100001 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on July 8, 2013.
How much is contract HHSN26100001 worth?
The government has obligated $0 on HHSN26100001.
Is contract HHSN26100001 an order under another contract?
Yes. HHSN26100001 is a delivery order under HHSN261201300026I, an indefinite delivery contract.
Was contract HHSN26100001 competed?
The extent of competition for HHSN26100001 was competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award